Sector
PharmaceuticalsOpen
₹109.3Prev. Close
₹110.28Turnover(Lac.)
₹170.43Day's High
₹114Day's Low
₹108.152 Week's High
₹149.652 Week's Low
₹77.35Book Value
₹94.24Face Value
₹1Mkt Cap (₹ Cr.)
1,173.74P/E
15.17EPS
7.26Divi. Yield
0.452 May 2024
12:00 AM
Dividend
Dividend Amount: 0.5
25 Apr 2024
12:00 AM
Board Meeting
Agenda : Audited Result
12 May 2023
12:00 AM
AGM
Announcement Date: 12 May, 2023
2 May 2024
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 10.51 | 10.42 | 10.37 | 10.31 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 977.94 | 926.58 | 841.06 | 745.33 |
Net Worth | 988.45 | 937 | 851.43 | 755.64 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|---|
Revenue | 636.35 | 465.51 | 441.95 | 426.59 |
yoy growth (%) | 36.7 | 5.33 | 3.6 | 43.2 |
Raw materials | -343.94 | -253.3 | -236.72 | -225.14 |
As % of sales | 54.04 | 54.41 | 53.56 | 52.77 |
Employee costs | -65.05 | -58.6 | -44.02 | -33.84 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|---|
Profit before tax | 123.65 | 91.18 | 121.71 | 120.01 |
Depreciation | -13.84 | -13.76 | -8.83 | -5.74 |
Tax paid | -33.73 | -23.68 | -29.37 | -45.57 |
Working capital | 73.23 | 16.34 | 44.64 | -0.64 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 36.7 | 5.33 | 3.6 | 43.2 |
Op profit growth | 19.39 | -8.69 | 7.58 | 5.23 |
EBIT growth | 34.17 | -24.46 | 2.52 | 31.32 |
Net profit growth | 37.27 | -26.89 | 24.04 | 30.55 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 770.24 | 751.59 | 747.45 | 577.21 | 689.31 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 770.24 | 751.59 | 747.45 | 577.21 | 689.31 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 28.74 | 17.79 | 31.49 | 20.22 | 39.19 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
Vibha G Sharma
Whole-time Director
Shruti Vishal Rao
Chairman & Independent Directo
Subramanian R Vaidya
Non-Exec. & Independent Dir.
Santosh Parab
Company Sec. & Compli. Officer
Aditi Bhatt
Non-Exec. & Independent Dir.
Shilpa Bhatia
Managing Director
Gagan Harsh Sharmma
Independent Director
Nandkumar Kashinath Chodankar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Bliss GVS Pharma Ltd
Summary
Bliss GVS Pharma Ltd is an export-oriented pharmaceutical company. It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Bliss GVS Pharma has presence in antimalarial, antifungal, antibacterial, anti-inflammatory and antibiotic therapeutic segments. It is a leading player in the antimalarial branded formulations segment. Bliss GVS Pharma is the only EU-GMP certified suppositories manufacturer in India.The company has a dedicated the R&D Centre for development of Suppositories, Semi Solids and Oral Solids with an experienced Team of over 50 Scientists for formulation development and analytical method development and certified by the Department of Scientific & Industrial Research (DSIR), Government of India.Incorporated in 1984 as a private limited company under the name Bliss Chemicals & Pharmaceuticals India Ltd, the company commenced its business in 1985. In 1994 the company introduced a new pharmaceutical product VAGID.During the financial year ended 31 March 2014, Bliss GVS Pharmas R&D center, received approval from Government of Indias Department for Scientific & Industrial Research (DSIR).During the year under review, the company invested in 51% share capital of Lifeon Labs Pvt Ltd. During the year under review, Bliss GVS Pharma faced challenges in Ghana, where delays in registration resulted in adverse regulatory action. However, the company took quick, corrective measures to resolve these issues. T
Read More
What is the Bliss GVS Pharma Ltd share price today?
The Bliss GVS Pharma Ltd shares price on N/A is Rs.₹111.7 today.
What is the Market Cap of Bliss GVS Pharma Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bliss GVS Pharma Ltd is ₹1171.54 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Bliss GVS Pharma Ltd?
The PE and PB ratios of Bliss GVS Pharma Ltd is 15.17 and 1.17 as of 22 Jul ‘24
What is the 52 Week High and Low of Bliss GVS Pharma Ltd?
The 52-week high/low is the highest and lowest price at which a Bliss GVS Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Bliss GVS Pharma Ltd is ₹77.65 and ₹148.95 as of 22 Jul ‘24
What is the CAGR of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd's CAGR for 5 Years at -6.86%, 3 Years at -0.88%, 1 Year at 13.26%, 6 Month at -12.99%, 3 Month at 0.46% and 1 Month at 7.52%.
What is the shareholding pattern of Bliss GVS Pharma Ltd?
The shareholding pattern of Bliss GVS Pharma Ltd is as follows:
Promoters - 34.97 %
Institutions - 21.33 %
Public - 43.71 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
